The Significance of Serum CA-125 Elevation in Chinese Patients with Primary Budd-Chiari Syndrome: A Multicenter Study
Table 4
Survival rate comparison between Budd-Chiari syndrome patients with different serum CA-125 after interventional treatment.
Increased CA-125 group*
Another group*
(>175 U/mL, )
(≤175 U/mL, )
Rate
95% confidence interval
Rate
95% confidence interval
Survival rate
3 months
95.6%
90.7%–98.9%
100%
97.4%–100%
4.33
0.037
6 months
95.6%
90.7%–98.9%
100%
97.4%–100%
12 months
95.6%
90.7%–98.9%
100%
97.4%–100%
24 months
95.6%
90.7%–98.9%
98.8%
96.4%–99.9%
Asymptotic survival rate
3 months
95.6%
90.8%–99.4%
100%
97.4%–100%
10.63
0.001
6 months
88.2%
80.5%–95.9%
99.4%
96.8%–99.9%
12 months
83.1%
74.3%–91.9%
97.0%
94.1%–99.8%
24 months
79.8%
69.5%–90.1%
92.0%
86.5%–97.5%
The Budd-Chiari syndrome patients with serum CA-125 5 times higher than the upper limit of normal range (>175 U/mL) were classified into group of increased CA-125; the other patients were classified into another group.
